Subscribe to the Novartis Oncology RSS Newsfeed to Receive Novartis Oncology Press Releases

Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash arcticnovartis Thu, 05/16/2024 - 11:34 Read more about Novartis meets all tender offer conditions ...

https://www.novartis.com/news/media-releases/novartis-meets-all-tender-offer-conditions-acquire-morphosys-ag-eur-68-share-cash

Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA arcticnovartis Wed, 05/15/2024 - 16:02 Read more ...

https://www.novartis.com/news/media-releases/novartis-highlights-pioneering-innovation-cml-data-from-scemblix-phase-iii-asc4first-study-newly-diagnosed-patients-asco-and-eha

Novartis receives FDA Breakthrough Therapy designation for Scemblix® in 1L CML angilma1 Fri, 05/10/2024 - 10:14 Read more about Novartis receives FDA Breakthrough Therapy designation for Scembl...

https://www.novartis.com/news/novartis-receives-fda-breakthrough-therapy-designation-scemblix-1l-cml

Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies arcticnovartis Mon, 05/06/2024 - 15:32 Read more about Novartis and Medicin...

https://www.novartis.com/news/media-releases/novartis-and-medicines-malaria-venture-announce-positive-efficacy-and-safety-data-novel-treatment-babies

Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline arcticnovartis Mon, 05/06/2024 - 15:32 Read more about Novartis enters agreement to acquire Mari...

https://www.novartis.com/news/media-releases/novartis-enters-agreement-acquire-mariana-oncology-strengthening-radioligand-therapy-pipeline

From black holes to AI driven drug discovery – collaboration wins the day metzgma4 Thu, 04/25/2024 - 15:02 Read more about From black holes to AI driven drug discovery – collaboration wins t...

https://www.novartis.com/stories/from-black-holes-ai-driven-drug-discovery-collaboration-wins-day

Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors arcticnovartis Tue, 04/23/2024 - 19:4...

https://www.novartis.com/news/media-releases/novartis-radioligand-therapy-lutathera-fda-approved-first-medicine-specifically-pediatric-patients-gastroenteropancreatic-neuroendocrine-tumors

Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised arcticnovartis Tue, 04/23/2024 - 07:04 Read more about Novartis delivers double-digit sales g...

https://www.novartis.com/news/media-releases/novartis-delivers-double-digit-sales-growth-and-core-margin-expansion-q1-fy-2024-guidance-raised

Novartis, au premier trimestre: croissance à deux chiffres du chiffre d’affaires et expansion de la marge core; hausse des prévisions pour 2024 arcticnovartis Tue, 04/23/2024 - 07:04 Read mo...

https://www.novartis.com/news/media-releases/novartis-au-premier-trimestre-croissance-deux-chiffres-du-chiffre-daffaires-et-expansion-de-la-marge-core-hausse-des-previsions-pour-2024

Novartis erzielt im ersten Quartal ein zweistelliges Umsatzwachstum und steigert die Kerngewinnmarge; Prognose für das Geschäftsjahr 2024 erhöht arcticnovartis Tue, 04/23/2024 - 07:04 Read mo...

https://www.novartis.com/news/media-releases/novartis-erzielt-im-ersten-quartal-ein-zweistelliges-umsatzwachstum-und-steigert-die-kerngewinnmarge-prognose-fur-das-geschaftsjahr-2024-erhoht